Andrea C Lo1, David Hodgson2, Jennifer Dang3, Scott Tyldesley4, Eric Bouffet5, Ute Bartels6, Sylvia Cheng7, Juliette Hukin7, Philippe L Bedard8, Karen Goddard9, Normand Laperriere2. 1. Princess Margaret Cancer Centre, Toronto, Ontario; British Columbia Cancer, Vancouver, British Columbia; University of Toronto, Toronto, Ontario; University of British Columbia, Vancouver, British Columbia. Electronic address: andrea.lo@bccancer.bc.ca. 2. Princess Margaret Cancer Centre, Toronto, Ontario; University of Toronto, Toronto, Ontario; The Hospital for Sick Children, Toronto, Ontario. 3. Princess Margaret Cancer Centre, Toronto, Ontario. 4. British Columbia Cancer, Vancouver, British Columbia; University of British Columbia, Vancouver, British Columbia. 5. University of British Columbia, Vancouver, British Columbia; The Hospital for Sick Children, Toronto, Ontario. 6. University of Toronto, Toronto, Ontario; The Hospital for Sick Children, Toronto, Ontario. 7. University of British Columbia, Vancouver, British Columbia; British Columbia Children's Hospital, Vancouver, British Columbia, Canada. 8. Princess Margaret Cancer Centre, Toronto, Ontario; University of Toronto, Toronto, Ontario. 9. British Columbia Cancer, Vancouver, British Columbia; University of British Columbia, Vancouver, British Columbia; British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Abstract
PURPOSE: The aim of this study was to determine the practice patterns and outcomes of intracranial germ cell tumors (IGCT) in adolescents and young adults according to different therapeutic approaches. METHODS AND MATERIALS: One-hundred twelve patients with IGCT aged 15 to 39 years were managed at either XX or the XY center from 1975 to 2015. The charts were retrospectively reviewed and data collected. RESULTS: Median duration of follow-up was 8.3 years. Ninety-four patients had germinomas, and 18 had nongerminomatous germ cell tumors (NGGCT). The primary disease sites were pineal gland (37 of 94 germinoma, 14 of 18 NGGCT) and suprasellar region (23 of 94 germinoma, 2 of 18 NGGCT). Eleven patients with germinoma (12%) and 2 patients with NGGCT (11%) had radiographic spinal metastases or positive lumbar cerebrospinal fluid cytology. Event-free survival (EFS) was 84% and overall survival (OS) was 90% at 10 years for germinoma; EFS was 71% and OS was 86% at 10 years for NGGCT. For patients with germinoma, 10-year EFS was 100% after craniospinal radiation therapy (CSRT) with chemotherapy (N = 10); 100% after whole-ventricular radiation therapy (WVRT), whole-brain radiation therapy (WBRT), or focal radiation therapy (FRT) with chemotherapy (N = 22); 90% after CSRT alone (N = 46); and 41% after WVRT, WBRT, or FRT alone (N = 16) (P < .0005). Ten-year OS was 100%, 100%, 90%, and 72%, respectively (P = .032). For patients with NGGCT, 10-year EFS was 80% after CSRT, WBRT, or WVRT plus chemotherapy (N = 10) versus 58% after FRT plus chemotherapy (N = 8) (P = .31); 10-year OS was 90% versus 58%, respectively (P = .16). CONCLUSIONS: We report excellent overall outcomes according to treatment approach in the largest study of IGCT in adolescents and young adults to our knowledge. EFS and OS were inferior after non-CSRT without chemotherapy in germinoma.
PURPOSE: The aim of this study was to determine the practice patterns and outcomes of intracranial germ cell tumors (IGCT) in adolescents and young adults according to different therapeutic approaches. METHODS AND MATERIALS: One-hundred twelve patients with IGCT aged 15 to 39 years were managed at either XX or the XY center from 1975 to 2015. The charts were retrospectively reviewed and data collected. RESULTS: Median duration of follow-up was 8.3 years. Ninety-four patients had germinomas, and 18 had nongerminomatous germ cell tumors (NGGCT). The primary disease sites were pineal gland (37 of 94 germinoma, 14 of 18 NGGCT) and suprasellar region (23 of 94 germinoma, 2 of 18 NGGCT). Eleven patients with germinoma (12%) and 2 patients with NGGCT (11%) had radiographic spinal metastases or positive lumbar cerebrospinal fluid cytology. Event-free survival (EFS) was 84% and overall survival (OS) was 90% at 10 years for germinoma; EFS was 71% and OS was 86% at 10 years for NGGCT. For patients with germinoma, 10-year EFS was 100% after craniospinal radiation therapy (CSRT) with chemotherapy (N = 10); 100% after whole-ventricular radiation therapy (WVRT), whole-brain radiation therapy (WBRT), or focal radiation therapy (FRT) with chemotherapy (N = 22); 90% after CSRT alone (N = 46); and 41% after WVRT, WBRT, or FRT alone (N = 16) (P < .0005). Ten-year OS was 100%, 100%, 90%, and 72%, respectively (P = .032). For patients with NGGCT, 10-year EFS was 80% after CSRT, WBRT, or WVRT plus chemotherapy (N = 10) versus 58% after FRT plus chemotherapy (N = 8) (P = .31); 10-year OS was 90% versus 58%, respectively (P = .16). CONCLUSIONS: We report excellent overall outcomes according to treatment approach in the largest study of IGCT in adolescents and young adults to our knowledge. EFS and OS were inferior after non-CSRT without chemotherapy in germinoma.
Authors: Didier Frappaz; Girish Dhall; Matthew J Murray; Stuart Goldman; Cecile Faure Conter; Jeffrey Allen; Rolf Dieter Kortmann; Daphne Haas-Kogen; Giovanni Morana; Jonathan Finlay; James C Nicholson; Ute Bartels; Mark Souweidane; Stefan Schönberger; Alexandre Vasiljevic; Patricia Robertson; Assunta Albanese; Claire Alapetite; Thomas Czech; Chin C Lau; Patrick Wen; David Schiff; Dennis Shaw; Gabriele Calaminus; Eric Bouffet Journal: Neuro Oncol Date: 2022-04-01 Impact factor: 13.029
Authors: Sydni M Cole; Sasmit Sarangi; David Einstein; Malgorzata McMasters; Ron Alterman; Jeffrey Bruce; Lauren Hertan; Helen A Shih; Eric T Wong Journal: Surg Neurol Int Date: 2021-05-25